JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $47
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to $47.
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to $47.